Erythropoietin's effect on lung fluid clearance in ARDS patients

The Effect of Erythropoietin on Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome

This study is testing if giving erythropoietin (EPO) can help patients with acute respiratory distress syndrome (ARDS) clear fluid from their lungs faster and improve their chances of surviving in the hospital.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 40 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Second Affiliated Hospital of Wenzhou Medical University (other)
• Locations: 1 site (Wenzhou, Zhejiang)
• Trial ID: NCT05857891 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the impact of erythropoietin (EPO) on alveolar fluid clearance in patients diagnosed with acute respiratory distress syndrome (ARDS). It is designed as a double-blind, randomized controlled trial where participants will receive either EPO or a placebo while being monitored in an intensive care unit. The study aims to determine if EPO can accelerate the resolution of alveolar edema and improve hospital survival rates. Participants will be closely screened and randomized to ensure unbiased results.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with ARDS and require mechanical ventilation.

Not a fit: Patients under 18, pregnant or lactating women, and those with certain medical conditions such as malignant tumors or recent thromboembolic disease may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve recovery outcomes for patients suffering from ARDS.

How similar studies have performed: While the use of erythropoietin in other contexts has shown promise, this specific application in ARDS is relatively novel and has not been extensively tested.

Eligibility criteria

Inclusion Criteria:

* Age≥18 years;
* Meeting diagnostic criteria for sepsis 3.0;
* Tracheal intubation and mechanical ventilation;
* Meeting the diagnostic criteria of ARDS Berlin;
* Willing to accept treatment and sign an informed consent form;

Exclusion Criteria:

* Age \<18 years;
* Pregnancy or lactation;
* Patients with malignant tumors;
* Recombinant human erythropoietin (rhEPO) allergic patients;
* Hemoglobin (Hb) ≥120g/L;
* have recently taken rhEPO (within 3 months) or participated in other clinical trials;
* History of thromboembolic disease (pulmonary embolism, heart attack, cerebral infarction, arteriovenous thrombosis);
* Inability or unwillingness to provide informed consent or to comply with the requirements of the study;

Where this trial is running

Wenzhou, Zhejiang

• SAHWenzhouMU — Wenzhou, Zhejiang, China (RECRUITING)

Study contacts

• Study coordinator: Shengwei Jin, Professor

Conditions: Acute Respiratory Distress Syndrome, Erythropoietin, ARDS, Lung Water Clearance